See more : After You Public Company Limited (AU.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Bellicum Pharmaceuticals, Inc. (BLCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bellicum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- IZOBLOK S.A. (IZB.WA) Income Statement Analysis – Financial Results
- Diamond Biotechnology Co., Ltd (6815.TWO) Income Statement Analysis – Financial Results
- Kesar Petroproducts Limited (KESARPE.BO) Income Statement Analysis – Financial Results
- Liberty Resources Acquisition Corp. (LIBY) Income Statement Analysis – Financial Results
- Stepan Company (SCL) Income Statement Analysis – Financial Results
Bellicum Pharmaceuticals, Inc. (BLCM)
About Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.50M | 6.20M | 500.00K | 7.14M | 1.12M | 185.00K | 388.00K | 282.00K | 1.78M | 1.94M | 1.47M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.50M | 6.20M | 500.00K | 7.14M | 1.12M | 185.00K | 388.00K | 282.00K | 1.78M | 1.94M | 1.47M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 22.76M | 23.58M | 39.05M | 64.54M | 71.15M | 65.66M | 51.26M | 33.56M | 11.01M | 7.05M | 5.80M |
| General & Administrative | 5.72M | 7.01M | 15.53M | 29.97M | 25.43M | 21.91M | 17.51M | 15.86M | 5.40M | 2.81M | 1.94M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.72M | 7.01M | 15.53M | 29.97M | 25.43M | 21.91M | 17.51M | 15.86M | 5.40M | 2.81M | 1.94M |
| Other Expenses | 0.00 | 7.00K | 112.00K | -2.99M | 436.00K | 864.00K | 580.00K | 3.18M | 43.21B | 0.00 | 0.00 |
| Operating Expenses | 28.48M | 30.59M | 54.58M | 94.51M | 96.59M | 87.57M | 68.77M | 49.42M | 16.41M | 9.86M | 7.74M |
| Cost & Expenses | 28.48M | 30.59M | 54.58M | 94.51M | 96.59M | 87.57M | 68.77M | 49.42M | 16.41M | 9.86M | 7.74M |
| Interest Income | 0.00 | 32.00K | 387.00K | 1.35M | 1.64M | 1.06M | 909.00K | 641.00K | 34.98K | 3.92K | 7.55K |
| Interest Expense | 46.00 | 4.00K | 2.66M | 4.28M | 4.20M | 3.67M | 1.76M | 12.00K | 1.76M | 50.72K | 1.41K |
| Depreciation & Amortization | -1.95M | 517.00K | -1.89M | 19.19M | 6.70M | 3.56M | 2.31M | 1.20M | 666.61K | 587.25K | 115.28K |
| EBITDA | -26.98M | -24.35M | 2.39M | -87.36M | -95.47M | -82.77M | -68.38M | -47.30M | -57.84B | -7.33M | -6.15M |
| EBITDA Ratio | -1,928.93% | -392.73% | -10,716.80% | -954.39% | -8,523.75% | -44,739.46% | -17,623.71% | -16,771.28% | -821.69% | -377.75% | -418.02% |
| Operating Income | -26.98M | -24.87M | -51.69M | -87.36M | -95.47M | -87.39M | -68.38M | -49.14M | -57.84M | -7.92M | -6.27M |
| Operating Income Ratio | -1,798.73% | -401.06% | -10,338.40% | -1,223.07% | -8,523.75% | -47,236.22% | -17,623.71% | -17,423.76% | -3,249.33% | -408.21% | -426.37% |
| Total Other Income/Expenses | 2.01M | 15.16M | -10.11M | -25.11M | -2.57M | -4.39M | -861.00K | 587.00K | -26.13M | -46.80K | 6.14K |
| Income Before Tax | -24.97M | -9.71M | -7.72M | -112.48M | -98.04M | -91.78M | -69.24M | -48.55M | -83.97M | -7.97M | -6.26M |
| Income Before Tax Ratio | -1,664.73% | -156.53% | -1,544.40% | -1,574.65% | -8,753.21% | -49,610.27% | -17,845.62% | -17,215.60% | -4,717.13% | -410.62% | -425.96% |
| Income Tax Expense | 2.00K | -127.00K | 897.00K | 13.62M | 1.63M | 3.67M | -1.46M | 12.00K | 1.09M | 3.92K | 7.55K |
| Net Income | -24.97M | -9.58M | -8.62M | -126.09M | -98.04M | -91.78M | -69.24M | -48.55M | -83.97M | -7.97M | -6.26M |
| Net Income Ratio | -1,664.87% | -154.48% | -1,723.80% | -1,765.25% | -8,753.21% | -49,610.27% | -17,845.62% | -17,215.60% | -4,717.13% | -410.62% | -425.96% |
| EPS | -0.81 | -0.83 | -1.50 | -26.92 | -24.37 | -28.94 | -25.69 | -18.43 | -33.47 | -8.11 | -6.37 |
| EPS Diluted | -0.81 | -0.83 | -1.50 | -26.92 | -24.37 | -28.94 | -25.69 | -18.43 | -33.47 | -8.11 | -6.37 |
| Weighted Avg Shares Out | 30.83M | 11.50M | 5.76M | 4.68M | 4.02M | 3.17M | 2.70M | 2.63M | 2.51M | 982.78K | 982.78K |
| Weighted Avg Shares Out (Dil) | 30.83M | 11.50M | 5.76M | 4.68M | 4.02M | 3.17M | 2.70M | 2.63M | 2.51M | 982.78K | 982.78K |
Bet on Rising P/E Investing With These Top 5 Stocks
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
Is Bellicum Pharmaceuticals Inc (BLCM) A Good Stock To Buy?
Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering
Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring
Tower Research Capital LLC TRC Acquires 4,745 Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)
4 Buckhead Business Organizations Are Coming Together
Source: https://incomestatements.info
Category: Stock Reports